Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

Yuri E. Nikiforov, MD, PhD
Published: Thursday, Mar 02, 2017



Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Some subtypes of thyroid cancer are indolent while others are very aggressive, Nikiforov explains. However, a certain type of thyroid cancer is very indolent and rarely causes harm to patients. While conducting long-term folllow-up of this specific patient population, research concluded that most of the patients lived a normal live and did not experience any adverse outcomes associated with the disease.

Therefore, the name is suggested to be reclassified as noninvasive follicular tumors, also known as a noninvasive follicular thyroid neoplasm with papillary-like nuclear features. They will no longer be labeled with the term cancer, he adds.


Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Some subtypes of thyroid cancer are indolent while others are very aggressive, Nikiforov explains. However, a certain type of thyroid cancer is very indolent and rarely causes harm to patients. While conducting long-term folllow-up of this specific patient population, research concluded that most of the patients lived a normal live and did not experience any adverse outcomes associated with the disease.

Therefore, the name is suggested to be reclassified as noninvasive follicular tumors, also known as a noninvasive follicular thyroid neoplasm with papillary-like nuclear features. They will no longer be labeled with the term cancer, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x